Ten years ago, Mark Davis was a chemical engineer with a successful career-until his wife Mary was diagnosed with breast cancer. Mary described her treatments as so unbearable that "she wanted to die." She turned to Mark and said, "there's got to be a better way-you can fix this." Mark felt like saying, "But I don't know squat about cancer." Instead, he immersed himself in a new field. Ten years later, Ray Natha, a pancreatic cancer patient with 3 months to live, agrees to be the first subject to be treated with IT-101, the nanoparticle drug Davis engineered. But will it work? And if it does, what are the implications for cancer treatment as we know it?